# First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

> **NCT06134531** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 31 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MR001

## Key facts

- **NCT ID:** NCT06134531
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06134531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06134531, "First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06134531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*